The specter of generic competition has repeatedly loomed around copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of connected medicinal ventures. While first times saw impressive gains, the patent end has created the way for discounted alternatives, potentially diminishing profitability and presenting a genuine hazar